Verve Therapeutics Inc (NASDAQ:VERV) has a beta value of 1.87 and has seen 0.68 million shares traded in the recent trading session. The company, currently valued at $382.27M, closed the recent trade at $4.30 per share which meant it lost -$0.27 on the day or -5.80% during that session. The VERV stock price is -207.91% off its 52-week high price of $13.24 and 0.0% above the 52-week low of $4.30. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.04 million shares traded. The 3-month trading volume is 1.44 million shares.
The consensus among analysts is that Verve Therapeutics Inc (VERV) is Buy stock at the moment, with a recommendation rating of 1.40. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 2 out of 8 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.65.
Verve Therapeutics Inc (NASDAQ:VERV) trade information
Sporting -5.80% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the VERV stock price touched $4.30 or saw a rise of 26.87%. Year-to-date, Verve Therapeutics Inc shares have moved -23.67%, while the 5-day performance has seen it change -26.28%. Over the past 30 days, the shares of Verve Therapeutics Inc (NASDAQ:VERV) have changed -30.23%. Short interest in the company has seen 15.27 million shares shorted with days to cover at 10.83.
Wall Street analysts have a consensus price target for the stock at $14.5, which means that the shares’ value could jump 70.34% from the levels at last check today. The projected low price target is $14.0 while the price target rests at a high of $15.0. In that case, then, we find that the latest price level in today’s session is -248.84% off the targeted high while a plunge would see the stock gain -225.58% from the levels at last check today.
Verve Therapeutics Inc (VERV) estimates and forecasts
The company’s shares have lost -13.55% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -25.30%.
9 analysts offering their estimates for the company have set an average revenue estimate of 9.38M for the current quarter. 9 have an estimated revenue figure of 4.79M for the next ending quarter. Year-ago sales stood 5.7M and 6.69M respectively for this quarter and the next, and analysts expect sales will grow by 64.63% for the current quarter and -25.30% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -42.43% over the past 5 years. Earnings growth for 2025 is a modest -13.49% while over the next 5 years, the company’s earnings are expected to increase by 5.30%.
VERV Dividends
Verve Therapeutics Inc is expected to release its next earnings report on 2025-Feb-26 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Verve Therapeutics Inc (NASDAQ:VERV)’s Major holders
Insiders own 5.04% of the company shares, while shares held by institutions stand at 90.14% with a share float percentage of 94.92%. Investors are also buoyed by the number of investors in a company, with Verve Therapeutics Inc having a total of 248.0 institutions that hold shares in the company. The top two institutional holders are ALPHABET INC. with over 12.35 million shares worth more than $60.26 million. As of 2024-06-30, ALPHABET INC. held 14.6618% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 6.62 million shares as of 2024-06-30. The firm’s total holdings are worth over $32.31 million and represent 7.8598% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. As of Dec 31, 2024, the former fund manager holds about 2.40% shares in the company for having 2.13 shares of worth $9.14 million while later fund manager owns 1.83 shares of worth $7.83 million as of Feb 28, 2025, which makes it owner of about 2.06% of company’s outstanding stock.
